TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04354233

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity intervention with connected devices
Description: Participants randomized in the intervention arm will receive recommandations in physical activity. They will also receive an activity tracker Withings Steel to wear during 6 months. The tracker will be connected to the Withings Health Mate application and the ABLE02 application. Participants will be encouraged to practice at least three walking sessions weekly of more than 10 consecutive minutes. Concerning the number of steps per day, the first objective will be determined according to the 6-min walking distance and to participants' preferences and capacities. The objective will be recalculated monthly according to the number of steps performed the previous week and will be adapted by the physical activity (PA) instructor and participants. Phone calls with the participants are regularly planned. Weekly quizzes on PA and nutrition will be proposed through the ABLE02 application. A messaging system and a phone line will be available for participants to contact the study team.
Study: NCT04363892

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Optical and infrared imaging
Description: Acquiring images (photographs) of the skin
Study: NCT03092518

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgery
Description: Heated Intraperitonial Chemotherapy (HIPEC) with gastrectomy using cisplatin, mitomycin C and sodium thiosulfate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin (90 mg/m2) will be administered via circuit to the peritoneal cavity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitomycin C
Description: Mitomycin C 10 mg/m2 will be administered via circuit to the peritoneal cavity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium Thiosulfate
Description: Sodium thiosulfate will be administered by continuous intravenous infusion starting immediately prior to the chemotherapy perfusion and continuing for a total of 12 hours.
Study: NCT03741673

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Stereotactic Radiosurgery
Description: Undergo SRS
Study: NCT04541927

Intervention type: GENETIC
Intervention: Epigenetic signatures
Description: Epigenetic signatures (Dr Sadikovic' lab, London, Ontario, Canada)
Study: NCT06172023

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Silver Nanoparticles Irrigant
Description: Nanosilver irrigant solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Silver Nanoparticles Irrigant
Description: Nanosilver irrigant solution

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chitosan Nanoparticles Irrigant
Description: Chitosan nanoparticles irrigant solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chitosan Nanoparticles Irrigant
Description: Chitosan nanoparticles irrigant solution
Study: NCT04012450

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Epidural anesthesia
Description: Performing an epidural anesthesia

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: spina-epidural anesthesia
Description: Performing a spina-epidural anesthesia
Study: NCT04190472

Intervention type: DIAGNOSTIC_TEST
Intervention: IOP HPV test
Description: Immediately after the LEEP, a cervical sample was taken for the IOP-HPV test
Study: NCT02583841

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Scaling and root planing
Description: scaling and root planing as an intervention was done in patients of the test group
Study: NCT01495013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day
Study: NCT03993470

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Short foot excercise for intrinsec muscles of the foot
Description: to examine the effects of the SFE compared to a placebo exercise in the foot posture index after a daily period of 4 weeks.
Study: NCT04229290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Switch of virally suppressed participants to Dolutegravir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir
Description: Switch of virally suppressed participants to Dolutegravir
Study: NCT02543151

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SpyGlass (direct visualization system) choledochoscopy
Description: SpyGlass (direct visualization system) choledochoscopy procedure will be performed pre and post biliary complication treatment
Study: NCT04413968

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Rapid detection test
Description: Rapid serological test by taking 3 drops of blood from the fingertip via the TDR device (rapid detection test) for children, supervising nursery staff and hospital laboratory and administrative staff

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Description: Posterior nasopharyngeal swabbing in children

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Stool collection
Description: Stool collection in children
Study: NCT01261624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: 1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Givinostat
Description: 1.0 mg/kg daily (0.5 mg/kg twice a day) in fed condition 1.5 mg/kg daily (0.75 mg/kg twice a day) in fed condition
Study: NCT04408534

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mode of noninvasive ventilation
Description: administration of during 3 hours each 4 cycles

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mode of noninvasive ventilation
Description: administration of during 3 hours each 4 cycles
Study: NCT01156896

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose in the fasting state.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal with added oil.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ferrous sulfate
Description: Ferrous sulfate, \~0.1 mg Fe/kg body weight, given as a single dose with a standard Thai rice meal.
Study: NCT02404857

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEG based Brain Computer Interface
Description: Using EEG signals to classify brain activity being 'rest' or 'active' to control the attached pneumatic glove and close the sensory-motor loop between intentional/mental movement and physical (though passive) movement.
Study: NCT03686215

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Study Device Arm
Description: LUM015 will be administered 2 to 6 hours prior to surgery. The LUM Imaging device will be used to assist in the removal of additional tumor tissue.
Study: NCT01720849

Intervention type: DRUG
Intervention: Fampyra
Description: The will be given as per normal patient treatment plan
Study: NCT03601494

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: perineural injection of platelet-rich plasma
Description: Sonographic guided injection was done under complete sterile conditions including skin sterilization, ultrasound probe covered with sterile pad, and a sterile gel. The needle was introduced from the lateral side toward midline using the in-plane approach to target the desired nerve, each nerve was injected by a single dose of 1.5 cc of PRP. Free hand one-man technique was used by the physician who simultaneously managed the ultrasound device by holding the syringe with one hand while scanning the nerve by moving the probe with the other hand. With continuous imaging of the tip of the needle, the syringe was put around the nerve and platelet-rich plasma was injected in the peri-neural tissue.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: medical
Description: vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: medical
Description: vitamin B complex, α lipoic acid, selective serotonin reuptake inhibitor (SSRI)
Study: NCT00003850

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: thalidomide
Study: NCT00869687

Intervention type: DEVICE
Group type: OTHER
Intervention: Poly-L-Lactic Acid Injection
Description: 0.05 mL of poly-l-lactic acid will be injected as depot at three (3) points (a total of 0.15 mL).
Study: NCT02359344

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CNV1014802

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04348279

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: propylene mesh
Description: propylene mesh as a palatal stent for palatal wound

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: propylene mesh
Description: propylene mesh as a palatal stent for palatal wound
Study: NCT04470778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986256
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Specified dose on specified days
Study: NCT02215096

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2636771
Description: GSK is available as 100 mg hard gelatin oral capsule to be taken once daily/continuous until treatment withdrawal under fasting conditions for at least 1hour (h) before and 2h after dosing with approximately 200 mL of water

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Description: Enzalutamide will be sourced locally from commercial stock for sites in countries where it is approved
Study: NCT04634383

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WFMA - wireless floating microelectrode array
Description: Wirelessly transmitted patterns of electrical stimulation will be delivered to the visual cortex of study participants to generate visual percepts.
Study: NCT01237938

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low Glycemic Diet
Description: Changing to low glycemic diet
Study: NCT01904227

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: standard outpatient DBT
Description: Patients receive 12 months of outpatient treatment as specified in the DBT manual (Linehan, 2002) in one of the participating regional psychiatric centers of Rivierduinen. The treatment is according to protocol and combines weekly individual cognitive-behavioral psychotherapy sessions with the primary therapist, weekly skills- training groups, if needed consultation and weekly consultation meetings for trainers and therapists.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inpatient Adaptation of DBT
Description: The intervention to be studied, inpatient DBT, consists of an inpatient program of 12 weeks. The department provides accommodation for 9 patients. Patients are admitted 5 days a week at the department Oost, part of the Jelgersma centre for Personality Disorders. Staff is only present in daytime. During the weekends the patients stay at home.~The therapy consists of DBT skills training (Linehan, 1996), individual psychotherapy (Linehan, 2002), crisis consultation if needed, and weekly meetings of the consultation team for all trainers and therapists for one hour. Staff also receives supervision twice-weekly.
Study: NCT01495013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride/10mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride/20mg Atorvastatin FDC
Description: 1 tablet by mouth once a day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 1mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 2mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4mg Glimepiride
Description: 1 tablet of Glimepiride and 1 tablet of Atorvastatin co-administered once daily
Study: NCT00406718

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Med-eMonitor
Description: Participants will use the Med-eMonitor™ device, which is an electronic device that holds up to one month's supply of up to five medications. It is capable of cueing the taking of medication, warning patients when they are taking the wrong medication or taking it at the wrong time, recording side effect complaints, and through modem hookup promptly alerting treatment staff of failures to take medication as prescribed.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PharmCAT
Description: Pharm CAT is a psychosocial intervention using environmental supports such as signs, alarms, checklists, and special medication containers to cue and sequence adaptive behavior in the patient's home environment. This treatment specifically targets adherence to medication, medication education, and orientation for patients with schizophrenia. Participants will receive weekly home visits from a case manager.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants receiving standard treatment will keep the Med-eMonitor™ device in their homes throughout the study but will not use its medication reminder function.
Study: NCT03078400

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL-108
Description: Subcutaneous injection of 150 mg administered either one time or two times per day.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPL-108
Description: Subcutaneous injection of 150 mg administered either one time or two times per day.
Study: NCT00137215

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Silverlon
Description: dressing for donor site mamagement
Study: NCT03521219

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib 500mg, once a day, oral of each 28 day cycle. Number of cycle: until progression or unacceptable toxicity develops.
Study: NCT04626024

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Withdrawal
Description: Stop taking TKI medication

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imatinib Mesylate, Dasatinib, Nilotinib or Bosutinib Re-initiation
Description: Re-start TKI medication
Study: NCT01231633

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozurdex
Description: Ozurdex, 0.7mg dexamethasone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin
Description: Formulated as a 1.25mg/0.05ml sterile solution given by intravitreal injection monthly as needed.
Study: NCT03993691

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tomo-E scan
Description: High-resolution limited-angle tomography positioning and examination will vary depending on injury.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiograph
Description: Standard of Care radiographic imaging of wrist.
Study: NCT02994589

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tegaderm™(Absorbant, 3M)
Description: 3M™ Tegaderm™ Dressing helps provide the natural moisture balance conducive to wound healing.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OASIS® wound matrix
Description: OASIS® Matrix is indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs' surgery, post-laser surgery, podiatric, wound dehiscence).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xeroform™
Description: Xeroform™ consists of a fine-mesh gauze impregnated with bismuth tribromophenate.
Study: NCT02898025

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Interferential Current
Description: Involves the application of medium frequency alternating currents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Interferential Current
Description: Involves the application of medium frequency alternating currents

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Laser
Description: Involves the application of low level laser over the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active Laser
Description: Involves the application of low level laser over the knee

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Interferential Current
Description: It is a sham interferential therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Interferential Current
Description: It is a sham interferential therapy

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Laser
Description: It is a sham laser therapy

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Laser
Description: It is a sham laser therapy
Study: NCT01495013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 10mg Atorvastatin
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20mg Atorvastatin
Description: 1 tablet of Atorvastatin and 1 tablet of Glimepiride co-administered once daily
Study: NCT02602652

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: a live attenuated chimeric JE vaccine
Description: The study included 2 visits (D0 and D28). At the first visit (D0), children were enrolled, collected the blood sample for evaluate the baseline immune status and given a JE-CV as a booster dose. After vaccination, children were observed for 30 minutes to monitor any immediate adverse events. Parents were given a digital thermometer for axillary temperature measurement, a ruler for measuring injection site reactions and a diary card for recording a solicited injection site and systemic reactions.~At the second visit (D28), blood samples were collected for evaluate the immunogenicity.
Study: NCT02264366

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Communication for Health Behavior management
Description: An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Communication for Health Behavior management
Description: An appropriate and evidence-informed model of motivational counselling, health coaching and chronic disease self-management will be integrated into the delivery of all aspects of the ACCELERATION program. The focus will be on 4 health behaviors that include healthy eating, exercise, smoking cessation and moderation of alcohol consumption. This will include engagement techniques such as motivational interviewing, identification of stage of change, visioning of best self, goal setting and action planning, expressing empathy, developing discrepancy, decisional balance, rolling with resistance, and supporting self-efficacy. (Rubak 2005, Knight 2006).
Study: NCT04873557

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Copper-based surfaces plus copper-enriched linen
Description: We will assess the efficacy of our intervention to decrease the acquisition of nasal and intestinal colonization with MDROs and the development of HAIs in the ICU setting.
Study: NCT03448276

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training in the vibrating platform
Description: 20-minute workout will be held, which will include: heating (5 minutes and stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walk
Description: Will be held 30 minutes of training, which will include the heating (5 minutes of stretching for the muscles quadriceps and sural triceps), 10 and 5 min of cooling.